Wound Management Technologies, Inc. Adds Veterans Health Administration Facilities to Growing List of Clients

FORT WORTH, Texas, Sept. 9 /PRNewswire/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that its subsidiary Wound Care Innovations LLC recently added the Veterans Health Administration facilities in Temple, Texas, and Gainesville, Florida, as new customers of Cellerate RX® Activated Collagen™.  These new customers mean that CellerateRx® is now being used by Veterans Health Administration facilities in Texas, Florida, Ohio, Colorado, Pennsylvania, Illinois, South Carolina, Wisconsin and California.  Physicians from the Denver and Miami VA hospitals recently published case studies on the clinical effectiveness of Cellerate RX®, which have supported the organic proliferation of this product line within the VA health system.  In addition, Wound Care Innovations, LLC exhibited at the second annual Save A Limb, Save A Life conference in Orlando, FL September 2-4.  The Save A Limb, Save A Life Foundation's goal is to reduce the number of lower extremity amputations and to improve the quality of life for citizens who are afflicted with wounds, complications of diabetes, and peripheral artery disease.  One of the Friday morning sessions was "The Role of Collagen in Wound Healing" by Dr. Gary Rothenberg, Director of Resident Training, Attending Podiatrist, Miami VA Healthcare System, and included information on the unique characteristics and benefits of Cellerate RX® in the management of diabetic wounds.   "It makes sense to me that if collagen is the key component of skin and we are trying to get a wound to epithelialize with skin, that we should definitely be using a collagen product like Cellerate," states Dr. Rothenberg. "I love having both the powder and gel form available to use with my patients. I have definitely seen increased compliance and efficacy with Cellerate RX® because of the unique feature of having both the gel and powder forms available to me as a clinician."

Ronald D. Mathis, Senior Vice President of Marketing and Sales for WNDM, who represented Cellerate RX® at the SALSAL conference along with Dr. Larry Baratta, its Vice President of Medical Affairs, said "We are excited about the prospect of increasing the adoption of Cellerate RX® by the Veterans Health Administration as one of its go-to wound care products.  Helping our veterans heal quickly while also assisting our government with saving money is a win-win for all stakeholders."

For Wound Management Technologies Shareholder Information please call 817-820-7077 or go to http://www.wmgtech.com

About Wound Care Innovations, LLC

Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM.ob - News) with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products.  For more information on Cellerate RX®, please visit the WCI web site at http://www.Cellerate RX® .com/.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, Cellerate RX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes.  Over the past 2 years Wound Management has focused on developing evidenced-based studies on Cellerate RX® and gaining physician awareness by participation in key industry conferences. Now Wound Management is focused on expanding sales through partnerships and contracted independent representatives. Wound Management has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage.  More information can be found on the company's web sites: http://www.wmgtech.com, http://www.Cellerate RX® .com , and http://www.secureehealth.com.

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Further Information: Shareholder Relations-Communications (817)820-7077

SOURCE Wound Management Technologies, Inc.